Revvity Stock Forum

The stock appears overpriced with high beta causing amplified price movements. Despite Revvity's positive outlook, the current price surpasses industry peers, suggesting caution before investing.

Despite Revvity's promising earnings outlook, its costly stock could spur selling by shareholders and deter potential investors. It's advised to await a price dip before investing.

The company's management pointed to a decrease in demand from its pharma and biotech customers, leading to a revenue decline in its life sciences business.